Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Calcifediol→

Calcifediol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
19356-17-3
Molecular formula
C27H44O2
Molecular weight
400.6 g/mol
Drug class
25-hydroxyvitamin D3vitamin D prohormone and precursor of calcitriol
Mechanism of action
Calcifediol (25-hydroxyvitamin D3) is converted in the kidney and other tissues to 1,25-dihydroxyvitamin D (calcitriol), which activates the vitamin D receptor and regulates calcium, phosphate and parathyroid hormone homeostasis.
Indications / reported uses
  • Treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency using the extended-release formulation; immediate-release products may have different vitamin D deficiency indications

Sources: US DailyMed — RAYALDEE (extended-release calcifediol) · NLM MeSH — Calcifediol · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

25-hydroxyvitamin D3; vitamin D prohormone and precursor of calcitriol

Mechanism of action

Calcifediol (25-hydroxyvitamin D3) is converted in the kidney and other tissues to 1,25-dihydroxyvitamin D (calcitriol), which activates the vitamin D receptor and regulates calcium, phosphate and parathyroid hormone homeostasis.

General use cases

  • Treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency using the extended-release formulation; immediate-release products may have different vitamin D deficiency indications

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Calcifediol Environmental Risk Assessment (ERA) (the Calcifediol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.